PE4398A1 - Composiciones farmaceuticas que incrementan la biodisponibilidad de inhibidores de proteinasas - Google Patents

Composiciones farmaceuticas que incrementan la biodisponibilidad de inhibidores de proteinasas

Info

Publication number
PE4398A1
PE4398A1 PE1996000408A PE00040896A PE4398A1 PE 4398 A1 PE4398 A1 PE 4398A1 PE 1996000408 A PE1996000408 A PE 1996000408A PE 00040896 A PE00040896 A PE 00040896A PE 4398 A1 PE4398 A1 PE 4398A1
Authority
PE
Peru
Prior art keywords
bioavailability
increase
pharmaceutical compositions
proteinase inhibitors
virically
Prior art date
Application number
PE1996000408A
Other languages
English (en)
Inventor
Carole Anne Bailey
Navnit Shah
Josephine Christine Ferdinando
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE4398A1 publication Critical patent/PE4398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

CARACTERIZADO PORQUE COMPRENDE: A) UN INHIBIDOR DE PROTEINASA, REFIRIENDOSE PREFERENTEMENTE AL N-TERT-BUTIL-DECAHIDRO-2-[2-(R)-HIDROXI-4-FENIL-3 (S) [[N-(2-QUINOLILCARBONIL)-L-ASPARRAGINIL]AMINO]BUTIL]-(4aS,8aS)-ISOQUINOLINA-3 (S) CARBOXAMIDA; B) UN PORTADOR FARMACEUTICAMENTE ACEPTABLE, QUE CONTIENE UN MONOGLICERIDO DE ACIDO GRASO C8-C10, DE INDICE DE ACIDO � 0,04, EN DONDE LA RELACION DE LA CONCENTRACION DEL MONOGLICERIDO SUFICIENTE PARA DISOLVER (A) ES APROXIMADAMENTE DE 3; C) POLIVINILPIRROLIDONA; D) DE 0,01% A 0,05% DE DL-O-TOCOFEROL. ESTOS GLICERIDOS USADOS COMO COMPONENTES PORTADORES DE LA FORMULACION, SOLUCIONAN LAS DIFICULTADES EXISTENTES POR EL CARACTER HIDROFOBICO Y/O LIPOFILICO DE (A), DE TAL MANERA QUE INHIBA LAS PROTEASAS DE ASPARTATO DE ORIGEN VIRICO, SIENDO UTILES EN PROFILAXIS O TRATAMIENTO DE INFECCIONES VIRICAS CAUSADAS PREFERENTEMENTE POR HIV
PE1996000408A 1995-06-06 1996-06-05 Composiciones farmaceuticas que incrementan la biodisponibilidad de inhibidores de proteinasas PE4398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
PE4398A1 true PE4398A1 (es) 1998-02-28

Family

ID=23860032

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000408A PE4398A1 (es) 1995-06-06 1996-06-05 Composiciones farmaceuticas que incrementan la biodisponibilidad de inhibidores de proteinasas

Country Status (18)

Country Link
US (1) US6008228A (es)
KR (1) KR100267437B1 (es)
AR (1) AR002759A1 (es)
CO (1) CO4700448A1 (es)
EG (1) EG24294A (es)
HR (1) HRP960271B1 (es)
MA (1) MA23900A1 (es)
MY (1) MY116525A (es)
PE (1) PE4398A1 (es)
RO (1) RO115113B1 (es)
SA (1) SA96170162B1 (es)
SI (1) SI0831826T1 (es)
SV (1) SV1996000040A (es)
TW (1) TW452492B (es)
UA (1) UA44316C2 (es)
UY (1) UY24248A1 (es)
YU (1) YU49308B (es)
ZA (1) ZA964448B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6353538B1 (en) * 1999-05-13 2002-03-05 Intel Corporation Protective cover and packaging for multi-chip memory modules
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
ATE381922T1 (de) * 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
WO2003070273A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf A bioadhesive agent
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
EP1715847A1 (en) * 2003-12-23 2006-11-02 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a hiv protease inhibitor6
CA2606386C (en) * 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Therapeutic compositions
EP2214635A1 (en) * 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ES2119748T3 (es) * 1990-03-23 1998-10-16 Yoshitomi Pharmaceutical Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0580778B1 (en) * 1991-04-19 1999-08-11 LDS Technologies, Inc. Convertible microemulsion formulations
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
NZ248332A (en) * 1992-08-07 1995-01-27 Sankyo Co Hiv protease inhibitor and its use
JPH08502492A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
EP0671929A4 (en) * 1992-10-16 1996-09-25 Smithkline Beecham Corp COMPOSITIONS.
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
ZA964448B (en) 1996-12-06
SV1996000040A (es) 1997-03-19
SA96170162B1 (ar) 2006-03-15
US6008228A (en) 1999-12-28
AR002759A1 (es) 1998-04-29
MY116525A (en) 2004-02-28
KR19990022425A (ko) 1999-03-25
YU33796A (sh) 1998-07-10
UA44316C2 (uk) 2002-02-15
EG24294A (en) 2009-01-08
HRP960271A2 (en) 1997-12-31
UY24248A1 (es) 2000-12-29
RO115113B1 (ro) 1999-11-30
KR100267437B1 (ko) 2000-12-01
YU49308B (sh) 2005-06-10
CO4700448A1 (es) 1998-12-29
HRP960271B1 (en) 2002-02-28
TW452492B (en) 2001-09-01
MA23900A1 (fr) 1996-12-31
SI0831826T1 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
PE4398A1 (es) Composiciones farmaceuticas que incrementan la biodisponibilidad de inhibidores de proteinasas
ATE231393T1 (de) Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend
MX9304972A (es) COMPOSICIONES DETERGENTES LIQUIDAS QUE CONTIENEN PROTEASA Y CIERTOS ACIDOS Y ESTERES ß-AMINOALQUILBORONICOS.
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
DK0999838T3 (da) Selv-emulgerende formulering for lipofile forbindelser
BR9507755A (pt) Composições géis em bastão compreendendo gelificantes oticamente enriquecidos
DE3862337D1 (de) Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten.
HUP0004396A2 (hu) A lipoprotein-oxidáció gátlására szolgáló, hatóanyagként hidroxilezett koleszterincsökkentő szert tartalmazó gyógyszerkészítmények
FI951250A0 (fi) Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot
HRP20010615B1 (en) Pharmaceutical compositions containing proton pump inhibitors
MY127749A (en) Liquid formulation
NZ515016A (en) HIV protease inhibitor composition
EA199800023A1 (ru) Фармацевтическая композиция, содержащая ингибитор протеиназы и моноглицерид
PT885881E (pt) Acidos sulfonilalcanoilamino hidroxietilamino sulfamicos uteis como inibidores de protease retroviral
FI935777A0 (fi) Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS
AR006833A1 (es) Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
JO2455B1 (en) New drug composition
ES2140512T3 (es) Composiciones farmaceuticas que contienen derivados de estaurosporina y un gliceridos polialquilenglicolico.
ATE205489T1 (de) N-substituierte azaheterocyclische carbonsäuren und ihre alkylester
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
IL114208A0 (en) Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
NZ506579A (en) Palatable oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term